Iovance Biotherapeutics (IOVA) is back in focus after real world data for its recently approved Amtagvi therapy showed a 44% confirmed objective response rate and 73% disease control in advanced melanoma patients.

Those Amtagvi results come as Iovance’s 7 day share price return of 11.67% and 90 day share price return of 14.80% contrast with a 1 year total shareholder return decline of roughly 50%. Recent momentum is improving from a weak longer term base.

If this kind of cancer therapy news has your attention, it could be a moment to see what else is emerging in the space through our screener of 27 healthcare AI stocks.

Iovance’s shares trade around US$2.87, with an intrinsic value estimate implying a sizeable discount and a long record of weak total returns. So is this a mispriced cancer therapy player, or is the market already assigning future growth expectations correctly?

Most Popular Narrative: 65.6% Undervalued

With Iovance Biotherapeutics last closing at $2.87 and the most followed narrative pointing to a fair value of $8.35, the gap between price and expectations is wide enough to pay attention to what is driving that view.

Advancing multiple late stage clinical programs for TIL therapies across solid tumor types (lung, endometrial, next-gen approaches) not only opens new addressable markets but also reduces reliance on Amtagvi alone, diversifying future revenue streams and stabilizing earnings outlook.

Curious how one approved therapy, several late stage programs, and a shift in margins are woven together into a single valuation story? The narrative leans heavily on faster revenue expansion, a move from sizeable losses toward profitability, and a future earnings multiple that assumes investor confidence holds up. If you want to see exactly how those pieces connect, the full breakdown lays out the numbers behind that $8.35 fair value.

Result: Fair Value of $8.35 (UNDERVALUED)

However, the story could change quickly if regulatory setbacks outside the US persist or if dependence on high priced Amtagvi makes reimbursement or demand more fragile than expected.

Next Steps

With sentiment clearly split between risk and opportunity, this is a good moment to act promptly, review the full data, and shape your own view with 2 key rewards and 3 important warning signs.

Ready to hunt for more ideas?

If Iovance has sharpened your interest in opportunities, do not stop here. Widen your search with targeted stock ideas that match the way you like to invest.

• Target potential mispricings by reviewing 54 high quality undervalued stocks that our filters surface for closer inspection.
• Strengthen your focus on balance sheet quality by scanning the solid balance sheet and fundamentals stocks screener (43 results) to see which companies pass stricter financial checks.
• Get ahead of the crowd by checking the screener containing 23 high quality undiscovered gems before attention and expectations catch up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.